Vivo Capital

Type

Venture Capital, Private equity

Status

Active

Location

Palo Alto, United States

Total investments

220

Average round size

61M

Portfolio companies

152

Rounds per year

7.86

Lead investments

31

Follow on index

0.31

Exits

89

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsManufacturingMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

In 1997 was created Vivo Capital, which is appeared as VC. The venture was found in North America in United States. The main office of represented VC is situated in the Palo Alto.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Vivo Capital, startups are often financed by Sofinnova Investments, OrbiMed, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are InterWest Partners, Frazier Healthcare Partners, Aisling Capital. In the next rounds fund is usually obtained by Sofinnova Investments, Aisling Capital, Technology Partners.

The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline ZAI Lab, Harmony Biosciences, Passage Bio Among the most popular fund investment industries, there are Medical, Genetics.

This organization was formed by Edgar G. Engleman. The overall number of key employees were 11.

Comparing to the other companies, this Vivo Capital performs on 11 percentage points more the average number of lead investments. The fund is constantly included in 2-6 investment rounds annually. When the investment is from Vivo Capital the average startup value is 100-500 millions dollars. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2015. The common things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations.

Show more

Investor highlights

Industry focus
HealthcareBiotech/Life SciencesMedtech
Stage focus
Series ASeries BSeries CSeries DSeries E Show 1 more
Geo focus
AlbaniaAustriaBahrain Show 74 more

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
220
Lead investments
31
Exits
89
Rounds per year
7.86
Follow on index
0.31
Investments by industry
  • Biotechnology (165)
  • Health Care (132)
  • Pharmaceutical (89)
  • Therapeutics (70)
  • Medical (69)
  • Show 56 more
Investments by region
  • United States (172)
  • China (30)
  • United Kingdom (7)
  • Singapore (2)
  • France (1)
  • Show 6 more
Peak activity year
2021
Number of Unicorns
1
Number of Decacorns
1
Number of Minotaurs
9

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
13
Avg. valuation at time of investment
73M
Group Appearance index
0.95
Avg. company exit year
10
Avg. multiplicator
3.35
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Ajax Therapeutics 13 May 2024 Biotechnology, Medical, Life Science Late Stage Venture 95M United States, Massachusetts, Cambridge
EpiBiologics 20 Jul 2023 Biotechnology, Health Care, Medical, Therapeutics Early Stage Venture 23M United States, California, San Mateo

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.